-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
As of early April 2021, the new crown pneumonia pandemic has affected more than 1.
Coronavirus disease
Denmark and Norway Science Center is the purpose of the study was to evaluate cooperation 28 days after vaccination ChAdOx1-S medsci.
medsci.
The 18-65-year-old population who received the first dose of ChAdOx1-S between February 9, 2021 and March 11, 2021 were included.
thrombus
The vaccinated cohort included 148,792 people (median age 45 years, 80% women) in Denmark and 132,472 people (median age 44 years, 78% women) in Norway, who received the first dose of ChAdOx1-S.
59 venous thromboembolic events were observed in the vaccination cohort.
In the Oxford-AstraZeneca covid-19 vaccine (ChAdOx1-S) large two-country cohort study of 18-65-year-old patients, the results showed that most cardiovascular and hemostatic results are reliable.
The study found that the incidence of embolism (including cerebral venous thrombosis) after ChAdOx1-S vaccination was higher than normal.
The incidence of embolism (including cerebral venous thrombosis) after ChAdOx1-S vaccination is higher than normal.
PottegårdA ,LundLC ,Karlstad/span> ,DahlJ , Andersen M , Hallas J et al.
Pottegård A , Lund LC , Karlstad /span> , Dahl J , Andersen M , Hallas J et al.
Leave a message here
